Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer

被引:25
作者
Fujitaka, K
Oguri, T
Isobe, T
Fujiwara, Y
Kohno, N
机构
[1] Hiroshima Univ, Fac Med, Dept Internal Med 2, Minami Ku, Hiroshima 7348551, Japan
[2] Natl Inst Hlth Sci, Pharmaceut & Med Devices Evaluat Ctr, Evaluat Div 2, Tokyo 158, Japan
关键词
CYP3A4; docetaxel; induction; RT-PCR;
D O I
10.1007/s002800100291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several recent studies have demonstrated that the cytochrome p450 (CYP) family plays an important role in the metabolism of taxanes. However. the role of CYP gene expression in tumors and peripheral mononuclear cells (PMN) is unknown. We therefore investigated the levels of CYP3A4 and CYP2C gene expression using reverse transcription polymerase chain reaction (RT-PCR) in PMN from 16 previously untreated lung cancer patients to determine whether the expression of the two genes is induced by docetaxel (TXT). Neither the CYP3A4 nor the CYP2C gene was induced after administration of carboplatin (CBDCA) alone. Expression of the CYP3A4 gene was induced by the administration of TXT alone or TXT and CBDCA. but expression of the CYP2C gene was unaffected. We also measured the expression of both genes using RT-PCR in 20 autopsy samples (ten non-small-cell lung cancers and their corresponding normal lung tissues) obtained from patients who had not received any chemotherapy during life. The level of CYP2C gene expression in samples of lung cancer was significantly higher than in normal lung tissue. but the level of CYP3A4 gene expression was not. These results suggest that the CYP3A4 gene is induced by TXT, and that it plays an important role in intracellular TXT metabolism.
引用
收藏
页码:42 / 46
页数:5
相关论文
共 35 条
  • [1] ANDERSON CD, 1995, DRUG METAB DISPOS, V23, P1286
  • [2] Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
    Ando, Y
    Tateishi, T
    Sekido, Y
    Yamamoto, T
    Satoh, T
    Hasegawa, Y
    Kobayashi, S
    Katsumata, Y
    Shimokata, K
    Saito, H
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) : 1587 - 1588
  • [3] Expression and localization of CYP3A4 and CYP3A5 in human lung
    Anttila, S
    Hukkanen, J
    Hakkola, J
    Stjernvall, T
    Beaune, P
    Edwards, RJ
    Boobis, AR
    Pelkonen, O
    Raunio, H
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) : 242 - 249
  • [4] Baker SD, 1997, PHARMACOTHERAPY, V17, pS126
  • [5] Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
    Bruno, R
    Hille, D
    Riva, A
    Vivier, N
    Huinnink, WWTB
    van Oosterom, AT
    Kaye, SB
    Verweij, J
    Fossella, FV
    Valero, V
    Rigas, JR
    Seidman, AD
    Chevallier, B
    Fumoleau, P
    Burris, HA
    Ravclin, PM
    Sheiner, LB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 187 - 196
  • [6] Clinical pharmacokinetics of docetaxel
    Clarke, SJ
    Rivory, LP
    [J]. CLINICAL PHARMACOKINETICS, 1999, 36 (02) : 99 - 114
  • [7] OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE
    COLE, SPC
    BHARDWAJ, G
    GERLACH, JH
    MACKIE, JE
    GRANT, CE
    ALMQUIST, KC
    STEWART, AJ
    KURZ, EU
    DUNCAN, AMV
    DEELEY, RG
    [J]. SCIENCE, 1992, 258 (5088) : 1650 - 1654
  • [8] CRESTEIL T, 1994, CANCER RES, V54, P386
  • [9] Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: Need of comparative clinical trials in resistant patients
    D'Incalci, M
    [J]. ANNALS OF ONCOLOGY, 1997, 8 (12) : 1183 - 1184
  • [10] DUMONTENT C, 1997, CANCER RES, V56, P1091